腺苷蛋氨酸注射液治疗重度黄疸型肝炎60例临床观察

Clinical obseration of adenosylmethionine injection on severe jaundice hepatitis in 60 patients

目的:探讨应用腺苷蛋氨酸注射液治疗重度黄疸型肝炎的疗效。方法:120例病毒性肝炎患者,随机分治疗组(60例)和对照组(60例)。对照组以常规基础保肝治疗,治疗组在对照组所用方法的基础上加用腺苷蛋氨酸,观察2组患者的疗效、肝功能恢复情况及临床症状改善情况。结果:疗程结束后,ALT下降2组比较无明显差异(P>0.05);治疗组TBIL(31.2±9.6)μmol.L-1明显低于对照组(44.3±10.4)μmol.L-1(P<0.05);治疗组ALB(48.6±13.1)μmol.L-1和PTA(71.1±25.6)μmol.L-1明显高于对照组ALB(34.1±10.4)μmol.L-1、PTA(56.2±19.4)μmol.L-1,差异具有显著性(P<0.05),2组在治疗过程中,均未见不良反应。治疗组总有效率73.3%(44/60),对照组总有效率43.3%(26/60),治疗组优于对照组(P<0.05)。结论:腺苷蛋氨酸注射液治疗重度黄疸型肝炎能改善生化指标,加速黄疸消退,提高肝脏储备功能,且无明显不良反应,安全性高,值得进一步推广应用。

OBJECTIVE To study adenosylmethionine injection on severe jaundice hepatitis. METHODS 120 patients with viral hepatitis were randomly divided into treatment group （60 cases） and control group （60 cases）. The control group were treated with conventional liver protection therapy, the treatment group were given s-adenosylmethionine （SAMe） additionally. The effect, liver function and improvement of clinical symptoms in the two groups were observed. RESULTS The two groups showed no significant difference in ALT after treatment （P〉0. 05）; TBIL in treatment group was （31.2 ± 9. 6） μmol·L^-1, which was significantly lower than that of （44. 3 ± 10. 4） μmol·L^-1 in control group （P〈0. 05） ; ALB（48. 6 ± 13. 1）μmol·L^-1 and PTA（71.1 ± 25.6）μmol·L^-1 in treatment group were significantly higher than that of （34. 1 ± 10. 4）μmol·L^-1 and （56. 2 ± 19. 4） μmol·L^-1 in control group（P〈0. 05）. The total effective was 73. 3% （44/60） in treatment group, which was higher than that of 43. 3% （26/60） in control group （P〈0. 05）. There were no adverse reactions in the two groups. CONCLUSION SAMe injection for severe jaundice hepatitis couldan improve biochemical hepatitis, accelerated jaundice, the liver functional reserve, with no obvious side effects.